Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
Source: View publication →
In patients with relapsed or refractory multiple myeloma previously treated with lenalidomide and an anti-CD38 antibody, adding the novel oral CELMoD mezigdomide to carfilzomib and dexamethasone extended median progression-free survival to 18.0 months, significantly outperforming standard doublet therapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SUCCESSOR-2 trial establishes mezigdomide as a highly effective, oral next-generation combination backbone for treating relapsed or refractory multiple myeloma. By achieving nearly a year and a half of progression-free survival in patients failing front-line standard-of-care (including IMiDs and anti-CD38 monoclonals), MeziKd offers a powerful, accessible, off-the-shelf therapeutic option to establish durable disease control prior to or in lieu of T-cell redirecting therapies.
Historical Context
The treatment landscape of multiple myeloma has seen drastic improvements over the past two decades with the advent of proteasome inhibitors, immunomodulatory drugs (IMiDs like lenalidomide and pomalidomide), and anti-CD38 monoclonal antibodies. However, patients invariably relapse and face progressively shorter durations of response, creating an urgent unmet need for patients who are dual- or triple-class refractory. Mezigdomide belongs to a new class of oral targeted protein degraders called CELMoDs (Cereblon E3 Ligase Modulators). Engineered for rapid and profound degradation of the transcription factors Ikaros and Aiolos, mezigdomide overcomes resistance mechanisms to conventional IMiDs. SUCCESSOR-2 represents the first pivotal Phase 3 success for mezigdomide, validating the CELMoD platform in clinical practice.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of mezigdomide, a novel CELMoD, differ fundamentally from traditional IMiDs like lenalidomide to allow it to be effective in lenalidomide-refractory multiple myeloma?
Key Response
Mezigdomide is a Cereblon E3 ligase modulator. While both traditional IMiDs and CELMoDs bind to cereblon, mezigdomide has a highly optimized binding profile that leads to much deeper, faster, and more sustained ubiquitination and degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This enhanced target degradation allows it to overcome the resistance mechanisms that multiple myeloma cells develop against traditional IMiDs.
The SUCCESSOR-2 trial specifically enrolled patients previously treated with lenalidomide and an anti-CD38 antibody. Why is this specific patient population critical in modern multiple myeloma management, and how does the Mezi-Kd regimen address this clinical gap?
Key Response
In contemporary frontline multiple myeloma therapy, almost all patients receive lenalidomide and an anti-CD38 monoclonal antibody (like daratumumab). Consequently, at their first or second relapse, most patients are dual-refractory to these primary agents. Finding effective, accessible therapies for this specific refractory state is a major clinical challenge. The 18.0-month median PFS of Mezi-Kd provides a highly active, off-the-shelf triplet option for these difficult-to-treat patients without immediately necessitating complex cellular therapies.
Given the impressive PFS of 18.0 months with Mezi-Kd in SUCCESSOR-2, how do we sequence this regimen against T-cell redirecting therapies like bispecific antibodies or CAR-T cells in the early relapsed setting for a patient who is lenalidomide and anti-CD38 exposed?
Key Response
Fellows must weigh off-the-shelf small molecules against T-cell redirecting therapies. Mezi-Kd avoids the logistical hurdles, cytokine release syndrome, and neurotoxicity of CAR-T/bispecifics, making it ideal for rapid disease control. However, sequencing is critical: utilizing a potent CELMoD first might preserve T-cell health for future CAR-T, or conversely, early CAR-T might be preferred before the patient's immune system is exhausted by further lines of therapy. This requires nuanced patient-specific decision-making based on disease tempo and patient fitness.
With the introduction of highly potent CELMoDs like mezigdomide yielding prolonged progression-free survival in early relapse, how should we re-evaluate our traditional approach of continuous therapy versus considering minimal residual disease (MRD)-guided de-escalation?
Key Response
As triplet regimens like Mezi-Kd push early-relapse PFS to 18 months and beyond, cumulative toxicity (such as carfilzomib-induced cardiovascular events or CELMoD-related prolonged cytopenias) becomes a primary limiting factor. The attending must balance maximizing survival with preserving quality of life. This trial prompts a paradigm shift regarding whether highly potent targeted degradation can achieve deep enough responses to allow for treatment holidays or fixed-duration therapy in the relapsed setting.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
SUCCESSOR-2 utilized an open-label design for a novel oral agent combined with intravenous therapy. What specific statistical methods and endpoint assessments are required to mitigate performance and detection bias for the primary endpoint of progression-free survival in this design?
Key Response
In open-label trials, knowledge of treatment assignment can influence patient reporting, investigator decisions regarding dose modifications, and scan timing. A rigorous methodological critique requires evaluation of strict adherence to blinded independent central review (BICR) for imaging and serological markers, as well as rigorous sensitivity analyses (e.g., treating missing data or unblinded investigator-assessed progression as events) to ensure the reported PFS is a robust and unbiased estimate.
The control arm in this trial was carfilzomib and dexamethasone (Kd). Given the rapid evolution of myeloma standard-of-care, would a critical reviewer argue that a Kd doublet is an inadequate control arm for patients relapsing after lenalidomide and anti-CD38 antibodies, and how might this impact the study's editorial significance?
Key Response
A critical editor must evaluate if the control arm reflects contemporary real-world practice. While Kd was historically appropriate, modern standard-of-care for early relapse often utilizes triplet regimens (e.g., pomalidomide-based triplets or Kd plus selinexor). If the Kd control arm underperforms relative to current real-world expectations for triplet therapy, the magnitude of the experimental arm's clinical benefit may be artificially inflated, threatening the direct applicability of the trial's conclusions.
Should NCCN and ESMO guidelines be updated to include Mezi-Kd as a Category 1 preferred regimen for patients with relapsed/refractory multiple myeloma who are lenalidomide and anti-CD38 refractory, and how does the strength of this evidence compare to existing recommendations for pomalidomide-based triplets?
Key Response
Current guidelines recommend pomalidomide-based triplets (like PVd or Isa-Pd) or Kd alone for lenalidomide-refractory patients. The SUCCESSOR-2 trial provides definitive Phase 3 evidence that Mezi-Kd yields a substantial PFS benefit directly addressing the dual-refractory population. The committee must evaluate the safety profile and comparative efficacy to determine if Mezi-Kd should supersede pomalidomide triplets (which often have inferior outcomes in lenalidomide-refractory disease) as the new preferred standard of care in this treatment node.
Clinical Landscape
Noteworthy Related Trials
ASPIRE Trial
Tested
Carfilzomib, lenalidomide, and dexamethasone
Population
Patients with relapsed multiple myeloma
Comparator
Lenalidomide and dexamethasone
Endpoint
Progression-free survival
ENDEAVOR Trial
Tested
Carfilzomib and dexamethasone
Population
Patients with relapsed or refractory multiple myeloma
Comparator
Bortezomib and dexamethasone
Endpoint
Progression-free survival
CANDOR Trial
Tested
Daratumumab, carfilzomib, and dexamethasone
Population
Patients with relapsed or refractory multiple myeloma
Comparator
Carfilzomib and dexamethasone
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis